patients should use backup or non-oral contraception for 4 weeks after each dose change
There are, however, two studies that we can call on: Pentadecapeptide BPC 157 Interactions with Adrenergic and Dopaminergic Systems in Mucosal Protection in Stress (link) This study wasnt designed to find the comparison between two administration methods, but it did look at how different systems of the body would affect these two methods
But the contraindicated populations we do know include: Pregnant or nursing individuals : The safety of BPC-157 in pregnant or nursing individuals hasnt been established or investigated in research
Retatrutide, because it activates three receptor pathways at once, may cause more gastrointestinal discomfort at higher doses
A credible product COA must include HPLC purity above 98%, independent mass spec confirmation at approximately 1419 Da, and endotoxin data below 1 EU/mg
This is usually followed by an off-cycle period of at least the same duration to assess the results